Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2018.06.01
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients wi ...
PDF (203 KB)
2018.10.25
Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pf ...
PDF (182 KB)
2018.11.21
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib ...
PDF (246 KB)
2018.10.23
Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report
PDF (211 KB)
2018.05.08
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared ...
PDF (268 KB)
2018.09.24
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients wit ...
PDF (269 KB)
2018.10.17
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patient ...
PDF (286 KB)
2018.09.25
Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...
PDF (205 KB)
2018.10.03
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types ...
PDF (101 KB)
2018.12.17
Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
PDF (244 KB)
Showing 1 - 10 of 47 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...